Dr. Jay A. Berzofsky This is Me

Education

 View all 50 references Web References

1. 1. www.pharmabiz.com

   www.pharmabiz.com/article/detn - [Cached]

   Published on: 3/20/2008   Last Visited: 3/23/2008

   "A therapeutic vaccine may offer an advantage over treatments, such as monoclonal antibodies, that target a single site on a cancer cell because it may induce the production of several different antibodies that can target multiple regions on a receptor, making it harder for the tumor to mutate and escape the effects of therapy," said Jay A. Berzofsky, M.D., Ph.D., of the vaccine branch at NCI's Centre for Cancer Research (CCR).
   
   The research team, led by Berzofsky, along with Jong Myun Park, Ph.D., and Masaki Terabe, Ph.D., of the Vaccine Branch, and John Morris, M.D., of the Metabolism Branch of the CCR, conducted a series of experiments studying the effectiveness of a vaccine containing a modified form of adenovirus, a type of virus that primarily affects the respiratory tract, that expresses portions of neu (Ad-neuECTM) in the treatment of breast cancer in mice.
   ...
   "These results show the potential for a vaccine that induces antibodies to an overexpressed cell surface receptor such as HER2," said Berzofsky.

2. 2. www.eatg.org

   www.eatg.org/news/newsitem.php - [Cached]

   Published on: 12/14/2007   Last Visited: 12/29/2007

   Jay Berzofsky, MD, PhD, chief of the vaccine branch at the National Cancer Institute, suggested that the level of Ad5 antibodies "might be affecting the way the vaccine is taken up and processed and could potentially lead to an immune response against the vaccine component that skews more toward a Th2 type of immune response and a greater chance of infection." He suggested looking at cytokine profiles and immunoglobulin isotypes , evidence for some shift in the Th/Th2 balance.

3. 3. Bio - JayBerzofsky

   www.heprf.org/biojayberzofskyS - [Cached]

   Published on: 2/19/2004   Last Visited: 1/9/2008

   Jay A. Berzofsky, M.D., Ph. D | Steven M. Feinstone, MD
   ...
   Jay A. Berzofsky, M.D., Ph. D.
   
   Jay Berzofsky has been the Chief of the Molecular Immunogenetics and Vaccine Research Section of the Metabolism Branch of the National Cancer Institute, NIH, since 1987. He received a Bachelor of Arts Summa cum Laude in Chemistry from Harvard University in 1967, and then a Ph.D. and M.D. from Albert Einstein College of Medicine in 1971 and 1973, respectively, the latter in protein biochemistry and biophysics under J. Peisach, W.E. Blumberg, and B. L. Horecker. After an internship in medicine at the Massachusetts General Hospital and a postdoctoral fellowship with Alan N. Schechter and Christian B. Anfinsen, Dr. Berzofsky moved into immunology through collaborations with Drs.
   ...
   Dr. Berzofsky's research has focused on Ir genes, antigen processing and presentation by MHC class I and class II molecules, the structure of antigenic determinants recognized by T and B cells, and the application of these principles to the design of vaccines for AIDS, malaria, cancer, and viruses that cause cancer, such as hepatitis C virus. With regard to hepatitis C virus, he has identified multiple epitopes recognized by human T cells, enhanced one such epitope to make a more potent vaccine, and shown protection of a core DNA vaccine in HLA-transgenic mice challenged with a surrogate virus expressing the hepatitis C core. He has published over 300 scientific articles and book chapters. Dr. Berzofsky has received an number of awards, including the U.S. Public Health Service Superior Service Award, the 31st Michael Heidelberger Award, the McLaughlin Visiting Professorship, and the Australasian Society for Immunology Visiting Lectureship. He is the past President of the American Society for Clinical Investigation, and was recently elected a Fellow of the American Association for the Advancement of Science.